Las experiencias de Whitney revelan la discriminación por edad en los entornos de atención médica, un problema de larga data que está recibiendo nueva atención durante la pandemia de covid, que ha matado a más de medio millón de estadounidenses de 65 años y más.
A Wrenching Farewell: Bidding Adieu to My Primary Care Doctor After Nearly 30 Years
Long-term relationships between patients and doctors often enrich the quality of care and create deep emotional bonds. When the doctors retire or move on, saying goodbye can be hard.
Alzheimer’s Drug Targets People With Mild Cognitive Impairment. What Does That Mean?
The condition can be an early signal of Alzheimer’s disease, but not always. Other health concerns could be causing thinking or memory problems, and the new drug, Aduhelm, would not be appropriate for those patients.
Minister for Seniors at Famed Church Confronts Ageism and the Shame It Brings
Lynn Casteel Harper, a minister at the interdenominational Riverside Church in New York City, discusses the spiritual dimension of aging.
Clarity on Covid Count: Pandemic’s Toll on Seniors Extended Well Beyond Nursing Homes
The latest research shows that although deaths in nursing homes received enormous attention, far more older adults who perished from covid lived outside of institutions. People with dementia and other severe neurological conditions, chronic kidney disease and immune deficiencies were hit especially hard.
Restoring a Sense of Belonging: The Unsung Importance of Casual Relationships for Older Adults
Relationships with people you know only superficially can help develop a sense of belonging and provide motivation to engage in activities. Research has found that older adults who have a broad array of “weak” as well as “close” ties enjoy better physical and psychological well-being and live longer than people with less diverse social networks.
Doctors Weigh Pros and Cons of Prescribing Hot-Button Alzheimer’s Drug
The potential benefits of Aduhelm are small, its effectiveness is not certain, and even the FDA Thursday shifted its guidance on who should get the drug. But physicians are dealing with an onslaught of interest from patients and their families, and figuring out which patients are best positioned to be helped by the drug will be difficult.
Doctores sopesan pros y contras de recetar la nueva droga para el Alzheimer
Mientras médicos y expertos en políticas de salud debaten los méritos de Aduhelm, el primer fármaco para el Alzheimer aprobado en 18 años, los pacientes simplemente quieren saber: “¿me ayudará?”.
Paying Billions for Controversial Alzheimer’s Drug? How About Funding This Instead?
Aduhelm, approved by the Food and Drug Administration last month despite questions about its efficacy, could be prescribed to at least 1 million patients a year, for a price tag of about $56 billion. Experts suggest there might be better ways to spend that money.
Calming Computer Jitters: Help for Seniors Who Aren’t Tech-Savvy
Millions of older adults want to be comfortable going online and using digital tools to enhance their lives. But many need help. A number of groups around the country offer assistance.